Waking up Hepatitis B virus (HBV)'s chronic form to maximize attack by promoter-targeting therapies

唤醒乙型肝炎病毒 (HBV) 的慢性形式，通过启动子靶向疗法最大限度地发挥攻击作用

• 批准号: 486942
• 负责人: Kasinyabo Emmanuelle
• 金额: $ 0.44万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Miscellaneous Programs
• 财政年份: 2023
• 资助国家: 加拿大
• 起止时间: 2023-05-01 至 2023-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=486942&lang=en
• 关键词: Cell; Chronic; Dna; Drugs; Epigenetic; Hepatitis B; Hepatocytes; Protein; Therapies

INTRO: Hepatitis B virus (HBV) remains chronic due to the persistence of its chronic form, the covalently closed circular DNA (cccDNA), which remains hidden in the nucleus, wrapped around histones and untargeted by current therapies. Thus, in the strategy

简介：B肝炎病毒（HBV）由于其慢性形式的持续存在而保持慢性，共价闭合环状DNA（cccDNA）仍然隐藏在细胞核中，包裹在组蛋白周围，并且不被目前的治疗靶向。因此，在战略中